Homatropine Eye Drops - Uses, Dose, MOA, Brands, Side effects

Homatropine Eye Drops are used to produce mydriasis as in patients undergoing refractory surgery. It is also used in patients with uveitis.

Homatropine Eye Drops Uses:

  • Mydriasis and cycloplegia for refraction:

    • It is used to produce mydriasis before and after surgery (producing cycloplegia and mydriasis for refraction).
  • Optical aid:

    • It may be used as an optical aid in cases of axial lens opacities.
  • Uveitis:

    • It is used to treat the inflammatory conditions of the uveal tract.

Homatropine Dose in Adults

Note: Patients with heavily pigmented irides may require higher doses.

Homatropine Dose in the treatment of Refraction:

  • Ophthalmic: 2% or 5% solution:
    • Instill 1 to 2 drops into the affected eye.
    • The dose may be repeated in 5 to 10 minutes if necessary

Homatropine eye drops Dose in the treatment of Uveitis:

  • Ophthalmic: 2% or 5% solution:
    • Instill 1 to 2 drops into the affected eye every 3 to 4 hours or as advised by the physician.

Homatropine Dose in Cildrens

Note: Patients with heavily pigmented irides may require higher doses.

Homatropine dose in the treatment of Mydriasis and cycloplegia for refraction:

  • Infants ≥3 months, Children, and Adolescents:

    • Ophthalmic: 5% solution:
      • Instill 1 to 2 drops into the affected eye immediately before the procedure.
      • The dose may be repeated once in 5 to 10 minutes if required.

Homatropine eye drops dose in the treatment of Uveitis:

  • Infants ≥3 months, Children, and Adolescents:

    • Ophthalmic: 5% solution:
      • Instill 1 to 2 drops into the affected eye every 3 to 4 hours or as advised by the healthcare expert.

Pregnancy Risk Factor C

  • It has not yet been tested in human or animal pregnancies.

Use during breastfeeding:

  • It is unknown if the drug is excreted into breastmilk. It is recommended that breastfeeding mothers avoid using the drug.

Dose in Kidney Disease:

There are no dosage adjustments provided in the manufacturer’s labeling.

Dose in Liver disease:

There are no dosage adjustments provided in the manufacturer’s labeling.

Side effects of Homatropine eye drops:

  • Cardiovascular:

    • Edema
  • Central Nervous System:

    • Burning Sensation
    • Stinging Sensation
  • Dermatologic:

    • Eczema
  • Endocrine & Metabolic:

    • Increased Thirst
  • Gastrointestinal:

    • Xerostomia
  • Local:

    • Local Irritation
  • Ophthalmic:

    • Blurred Vision
    • Follicular Conjunctivitis
    • Increased Intraocular Pressure
    • Ocular Exudate
    • Photophobia
    • Vascular Congestion Of The Eye

Contraindications to Homatropine eye drops:

  • Patients who have had glaucoma in the past or are at high risk for developing it (such as those with narrow anterior rooms).
  • Allergy reactions to any component of the drug or the drug itself
  • Cross-reactivity to belladonna alkaloids may occur because of the similarities in structure, however, data is limited.

Warnings and precautions

  • CNS effects

    • Neurological symptoms may include confusion, delirium and agitation. Excessive use of medicine can cause neurologic symptoms.
    • Although neurological symptoms can occur in any age group, they are more common in children and the elderly.
    • Patients who are required to be alert for tasks such as driving heavy machinery or operating heavy machinery should not take this drug.
  • Ocular light sensitivity:

    • To avoid ocular hypersensitivity, patients should be taught to use sunglasses and appropriate eye protection after applying the eye drops.
  • Down syndrome

    • Angle-closure Glaucoma should be checked in patients with Down syndrome before they use the eye drops. These patients are more likely to develop angle-closure.
  • Keratoconus

    • Patients with Keratoconus should use it with caution as fixed pupillary dilation could occur.

Homatropine: Drug Interaction

Risk Factor C (Monitor therapy)

Acetylcholinesterase Inhibitors

May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.

Amantadine

May enhance the anticholinergic effect of Anticholinergic Agents.

Anticholinergic Agents

May enhance the adverse/toxic effect of other Anticholinergic Agents.

Botulinum Toxin-Containing Products

May enhance the anticholinergic effect of Anticholinergic Agents.

Cannabinoid-Containing Products

Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. Exceptions: Cannabidiol.

Chloral Betaine

May enhance the adverse/toxic effect of Anticholinergic Agents.

Gastrointestinal Agents (Prokinetic)

Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic).

Glucagon

Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.

Itopride

Anticholinergic Agents may diminish the therapeutic effect of Itopride.

Mianserin

May enhance the anticholinergic effect of Anticholinergic Agents.

Mirabegron

Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron.

Nitroglycerin

Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption.

Opioid Agonists

Anticholinergic Agents may enhance the adverse/toxic effect of Opioid Agonists. Specifically, the risk for constipation and urinary retention may be increased with this combination.

Ramosetron

Anticholinergic Agents may enhance the constipating effect of Ramosetron.

Thiazide and Thiazide-Like Diuretics

Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics.

Topiramate

Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate.

Risk Factor D (Consider therapy modification)

Pramlintide

May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.

Secretin

Anticholinergic Agents may diminish the therapeutic effect of Secretin. Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.

Risk Factor X (Avoid combination)

Aclidinium

May enhance the anticholinergic effect of Anticholinergic Agents.

Cimetropium

Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium.

Eluxadoline

Anticholinergic Agents may enhance the constipating effect of Eluxadoline.

Glycopyrrolate (Oral Inhalation)

Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation).

Glycopyrronium (Topical)

May enhance the anticholinergic effect of Anticholinergic Agents.

Ipratropium (Oral Inhalation)

May enhance the anticholinergic effect of Anticholinergic Agents.

Levosulpiride

Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride.

Oxatomide

May enhance the anticholinergic effect of Anticholinergic Agents.

Potassium Chloride

Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride. Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.

Potassium Citrate

Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.

Revefenacin

Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin.

Tiotropium

Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium.

Umeclidinium

May enhance the anticholinergic effect of Anticholinergic Agents.

Monitoring Parameters:

None mentioned. Monitor the response to treatment.

How to administer Homatropine eye drops?

Ophthalmic instillation:

  • Wash hands when instilling the eye drops and remove contact lenses. Avoid touching the tip of the applicator to the surrounding skin, eyelashes, or other ocular structures.
  • To reduce the chances of systemic absorption, press the lacrimal sac for 1 - 3 minutes after instilling the eye drops.
  • Contact lenses can be worn after 10 to 15 minutes. If the eyes are red or inflamed, avoid wearing contact lenses.

Mechanism of action of Homatropine:

  • It dilates pupils (mydriasis), and causes cycloplegic (loss of or paralysis) of accommodation. 
  • It inhibits the response of the ocular muscles to cholinergic stimulation (iris sphincter muscle and muscles of the ciliary organ).

International Brand Names of Homatropine eye drops:

  • Homatropaire
  • Isopto Homatropine
  • Bernardtropina
  • Bromhydrate d'homatropine-Chauvin
  • Hemasol
  • Hemomin
  • Homapin
  • Homarin Forte
  • Homatogen
  • Homatropin
  • HomatropinPOS
  • Homatropina
  • Homatropine
  • Homatropine Faure
  • Homo Grin
  • Isopto Homatropine
  • Isopto-Homatropine
  • Matropin
  • Minims Homatropine
  • Minims Homatropine Hydrobromide
  • Minims-Homatropinhydrobromid
  • Ocuhomapine
  • Omatropina
  • Paratropina

Homatropine Brand Names in Pakistan:

Homatropine (HBr) Eye Drops 2 %w/v in Pakistan

Homatropine Ethical Laboratories (Pvt) Ltd.

Comments

NO Comments Found